Skip to main content
. 2022 May 10;217:114827. doi: 10.1016/j.jpba.2022.114827

Table 3.

Subdivision of COVID-19 Severe patients by outcome in “survivors” and “non-survivors”; CAD: coronary artery diseases; HF: heart failure; PAD: peripheral artery disease; CKD: chronic kidney disease; COPD: Chronic obstructive pulmonary disease.

Severe “survivors” (20) Severe “non-survivors” (34) p-value
Sex F: 6 (30%); M: 14 (70%) F: 10 (29%); M: 24 (71%) 0.964
Age 65.00 ± 14.40 69.53 ± 9.47 0.169
CAD 5 (25.0%) 7 (20.6%) 0.673
HF 1 (5.0%) 1 (2.9%) 0.684
Obesity 6 (30.0%) 6 (17.6%) 0.196
Atrial Fibrillation 1 (5.0%) 4 (11.8%) 0.416
Valvular disease 1 (5.0%) 1 (2.9%) 0.662
PAD 1 (5.0%) 0.187
Dyslipidemia 5 (25.0%) 3 (8.8%) 0.108
Diabetes mellitus 4 (20.0%) 13 (38.2%) 0.277
Arterial hypertension 12 (60.0%) 20 (58.8%) 1.000
CKD 3 (15.0%) 4 (11.8%) 0.480
Smoking 6 (30.0%) 1 (2.9%) 0.090
COPD 3 (15.0%) 6 (17.6%) 0.776
Autoimmune disease 1 (5.0%) 3 (8.8%) 0.642